Reducing COVID-19 Trial Disruptions with Configurable RTSM Strategies
Signant worked with sponsors to quickly mitigate increasing challenges and avoid study interruptions.
This white paper summarizes the findings and best practices on navigating the pandemic in this whitepaper, arguing that RTSM systems need to be configurable and adaptable so as to minimize COVID-19 impacts on clinical trial patients.
The paper also discusses the recent distribution, screening, and enrollment challenges as well as their respective solutions.
This informational white paper is part of a compendium intended to share best practices and ongoing learnings related to the impact of COVID-19 on ongoing and planned clinical trials. Content is authored by a dedicated team of experienced scientists, clinicians, technologists, and data quality experts.
